Premium
An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography
Author(s) -
Hawkins Randall A.,
Choi Yong,
Scates Steven,
Rege Sheila,
Hoh Carl K.,
Glaspy John,
Phelps Michael E.
Publication year - 1993
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930530211
Subject(s) - positron emission tomography , medicine , in vivo , positron emission , nuclear medicine , glycolysis , positron , brain positron emission tomography , tomography , animal model , preclinical imaging , medical physics , radiology , nuclear physics , metabolism , physics , genetics , biology , electron
Abstract We developed a method for evaluating tumor glycolytic rates in vivo with nude mice injected with 2‐[F‐18]fluoro‐2‐deoxy‐d‐glucose (FDG) and a dedicated animal positron emission tomography (PET) scanner. Animals were injected with NR‐6 mouse fibroblast tumor cell lines. When tumors achieved a large enough size to be macroscopically visible, quantitative measurements of FDG uptake in vivo were obtained, using both standard nonlinear regression with the FDG tracer kinetic model to generate estimates of model parameters, including K NLR , the rate constant for net phosphorylation of FDG. Additionally, we determined the values of K PAT , the rate constant for net phosphorylation of FDG measured with a non‐iterative graphical method. Estimates of K were highly correlated (r = 0.95) with both methods, and parametric images of K PAT demonstrate both the tumor location and size, but are also scaled in units of phosphorylation of FDG. The method is suitable for serial studies of tumor glucose metabolism during and after therapeutic interventions, such as chemotherapeutic trials. © 1993 Wiley‐Liss, Inc.